# Securities and Exchange Commission

Type: organization

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/securities-and-exchange-commission-organization
Canonical HTML page: https://gethealthbrief.com/entity/securities-and-exchange-commission-organization

## Timeline

- **2026-03-12**: Remediation Begins — Internal IT teams and third-party forensic experts begin system restoration processes.
- **2026-03-11**: Attack Detected — Stryker identifies unauthorized activity and global network disruptions.
- **2026-03-11**: Public Disclosure — The company issues a statement confirming the cyberattack to media and stakeholders.

## Recent coverage (3 stories)

### Stryker Global Networks Disrupted by Major Cyberattack
2026-03-11 21:09:49 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Stryker, a leading global medical technology firm, has confirmed a significant cyberattack that has compromised its international network infrastructure. The incident marks another high-profile breach in the healthcare sector, raising concerns over supply chain stability for critical surgical and orthopedic equipment.
Full story: https://gethealthbrief.com/story/stryker-cyberattack-global-network-disruption

### Fisher Asset Management Boosts Eli Lilly Stake Amid GLP-1 Expansion
2026-03-03 00:58:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Fisher Asset Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. The move brings the firm's total holdings to over 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory.
Full story: https://gethealthbrief.com/story/fisher-asset-management-eli-lilly-stake-increase

### Essex Woodlands Trims EyePoint Pharmaceuticals Stake Amid Pipeline Focus
2026-02-28 00:58:31 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Essex Woodlands Management Inc. reduced its position in EyePoint Pharmaceuticals by 7.3% in the third quarter, while maintaining a significant $15.45 million stake. The move reflects a strategic rebalancing as EyePoint advances its late-stage ophthalmic pipeline, particularly its DURAVYU™ platform.
Full story: https://gethealthbrief.com/story/essex-woodlands-eyepoint-pharmaceuticals-stake-reduction

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.